Cramer on Merck & Co. MRK: Trading Like a Value Trap Despite Strong Fundamentals

According to market expert Jim Cramer, Merck & Co. (MRK) is currently trading like a value trap despite having strong fundamentals. Cramer believes that the stock is undervalued due to investors' concerns about the company's patent expiration for its blockbuster drug, Keytruda. However, Cramer points out that Merck has a diverse portfolio of other drugs that can offset the loss in revenue from Keytruda. He recommends seeking professional advice from Stocks Prognosis before making any investment decisions on Merck & Co. shares.